

<p>BSE Limited 1st Floor, P.J. Towers Dalal Street Mumbai – 400 001</p> <p>Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan</p>	<p>National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) Mumbai – 400 051</p> <p>Kind Attn.: Famroze Pochara Asst. Vice President</p>
<p>Date: August 29, 2018</p>	
<p>Re.: Press Release</p>	

Dear Sir / Madam,

We wish to inform that the USFDA inspected the injectables manufacturing facility of Liva Pharmaceuticals Ltd. (Liva) which is located at Vadodara, from 20th August 2018 to 28th August 2018. Liva is a 100% subsidiary of Cadila Healthcare Ltd.

This was a product specific Pre Approval Inspection. The inspection concluded with 5 observations. Liva will respond to the USFDA within 15 days. It may be noted that at present Liva does not export any products to the US market.

About Zydus Cadila


Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully,

For, CADILA HEALTHCARE LIMITED



UPEN H. SHAH
COMPANY SECRETARY

